RAPP vs. ANIP, DYN, INDV, AMPH, ARDX, EVO, ETNB, OCUL, GPCR, and IOVA
Should you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.
Rapport Therapeutics vs.
ANI Pharmaceuticals (NASDAQ:ANIP) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.
ANI Pharmaceuticals received 437 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Rapport Therapeutics an outperform vote while only 64.46% of users gave ANI Pharmaceuticals an outperform vote.
ANI Pharmaceuticals presently has a consensus target price of $79.75, suggesting a potential upside of 20.23%. Rapport Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 248.26%. Given Rapport Therapeutics' higher possible upside, analysts clearly believe Rapport Therapeutics is more favorable than ANI Pharmaceuticals.
76.1% of ANI Pharmaceuticals shares are held by institutional investors. 12.7% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Rapport Therapeutics has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Rapport Therapeutics' return on equity.
ANI Pharmaceuticals has higher revenue and earnings than Rapport Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 5 mentions for Rapport Therapeutics. ANI Pharmaceuticals' average media sentiment score of 1.04 beat Rapport Therapeutics' score of 0.31 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.
Summary
ANI Pharmaceuticals beats Rapport Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Rapport Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rapport Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RAPP) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy RAPP Stock Free RAPP Stock Alerts